MIATA cited

 TitleAuthorsJournalYearVolumeIssueBeginning Page
1Monitoring cytokine profiles during immunotherapySiebert, Janet C.; Walker, Edwin B.IMMUNOTHERAPY201026799
2Equivalence of ELISpot Assays Demonstrated between Major HIV Network LaboratoriesGill, Dilbinder K.; Huang, Yunda; Levine, Gail L.; et al.PLOS ONE2010512
3MHC-peptide tetramers for the analysis of antigen-specific T cellsSims, Stuart; Willberg, Christian; Klenerman, PaulEXPERT REVIEW OF VACCINES201097765
4T-cell recognition of chemicals, protein allergens and drugs: towards the development of in vitro assaysMartin, Stefan F.; Esser, Philipp R.; Schmucker, Sonja et al.CELLULAR AND MOLECULAR LIFE SCIENCES201067244171
5Dendritic Cells Are They Clinically Relevant?Palucka, Karolina; Ueno, Hideki; Roberts, Lee; Fay, Joseph; Banchereau, JacquesCANCER JOURNAL2010164318
6Overcoming the hurdles of randomised clinical trials of therapeutic cancer vaccinesSasada, Tetsuro; Komatsu, Nobukazu; Suekane, Shigetaka; Yamada, Akira; Noguchi, Masanori; Itoh, KyogoEUROPEAN JOURNAL OF CANCER20104691514
7Development and application of 'phosphoflow' as a tool for immunomonitoringWu, Sheng; Jin, Lei; Vence, Luis; Radvanyi, Laszlo G.EXPERT REVIEW OF VACCINES201096631
8Rational design of HIV vaccine and microbicides: report of the EUROPRISE annual conferenceWahren, Britta; Biswas, Priscilla; Borggren, Marie et al.JOURNAL OF TRANSLATIONAL MEDICINE20108
9Improved Endpoints for Cancer Immunotherapy TrialsHoos, Axel; Eggermont, Alexander M. M.; Janetzki, Sylvia; Hodi, F. Stephen; Ibrahim, Ramy; Anderson, Aparna; Humphrey, Rachel; Blumenstein, Brent; Old, Lloyd; Wolchok, JeddJOURNAL OF THE NATIONAL CANCER INSTITUTE2010102181388
10DNA vaccines against cancer come of ageStevenson, Freda K.; Ottensmeier, Christian H.; Rice, JasonCURRENT OPINION IN IMMUNOLOGY2010222264
11Surrogate end points in the design of immunotherapy trials: emerging lessons from type 1 diabetesRoep, Bart O.; Peakman, MarkNATURE REVIEWS IMMUNOLOGY2010102145
12Response definition criteria for ELISPOT assays revisitedMoodie, Z.; Price, L.; Gouttefangeas, C.; Mander, A.; Janetzki, S.; Loewer, M.; Welters, M. J. P.; Ottensmeier, C.; van der Burg, S. H.; Britten, Cedrik M.CANCER IMMUNOLOGY IMMUNOTHERAPY201059101489
13A model for harmonizing flow cytometry in clinical trialsMaecker, Holden T.; McCoy, J. Philip, Jr.NATURE IMMUNOLOGY20101111975
14Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunitySpeiser, Daniel E.; Romero, PedroSEMINARS IN IMMUNOLOGY2010223144
15An integrative paradigm to impart quality to correlative scienceKalos, MichaelJOURNAL OF TRANSLATIONAL MEDICINE20108
16Serum is not required for ex vivo IFN-gamma ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding ProgramMander, A.; Gouttefangeas, C.; Ottensmeier, C.; Welters, M. J. P.; Low, L.; van der Burg, S. H.; Britten, C. M.CANCER IMMUNOLOGY IMMUNOTHERAPY2010594619
17Evaluation of cellular immune responses in cancer vaccine recipients: lessons from NY-ESO-1Cebon, Jonathan; Knights, Ashley; Ebert, Lisa; Jackson, Heather; Chen, WeisanEXPERT REVIEW OF VACCINES201096617
18Critical parameters in blood processing for T-cell assays: Validation on ELISpot and tetramer platformsAfonso, Georgia; Scotto, Matthieu; Renand, Amedee; Arvastsson, Jeanette; Vassilieff, Dominique; Cilio, Corrado M.; Mallone, RobertoJOURNAL OF IMMUNOLOGICAL METHODS20103591-228
19New approaches to design HIV-1 T-cell vaccinesPerrin, Helene; Canderan, Glenda; Sekaly, Rafick-Pierre; Trautmann, LydieCURRENT OPINION IN HIV AND AIDS201055368
20Meeting Report from the Second "Minimum Information for Biological and Biomedical Investigations" (MIBBI) workshop.Kettner C, Field D, Sansone SA, et al. STAND GENOMIC SCI201033259
21Dendritic cells in cancer immunotherapySchuler GEUROPEAN JOURNAL OF IMMUNOLOGY20104082123
22Phase I Trial of a Personalized Peptide Vaccine for Patients Positive for Human Leukocyte Antigen-A24 With Recurrent or Progressive Glioblastoma MultiformeTerasaki, Mizuhiko; Shibui, Soichiro; Narita, Yoshitaka; Fujimaki, Takamitsu; Aoki, Tomokazu; Kajiwara, Koji; Sawamura, Yutaka; Kurisu, Kaoru; Mineta, Toshihiro; Yamada, Akira; Itoh, KyogoJOURNAL OF CLINICAL ONCOLOGY2011293337
23Strength of TCR-Peptide/MHC Interactions and In Vivo T Cell ResponsesCorse, Emily; Gottschalk, Rachel A.; Allison, James P.JOURNAL OF IMMUNOLOGY201118695039
24Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyondBritten, C. M.; Janetzki, S.; van der Burg, S. H.; Huber, C.; Kalos, M.; Levitsky, H. I.; Maecker, H. T.; Melief, C. J. M.; O'Donnell-Tormey, J.; Odunsi, K.; Old, L. J.; Pawelec, G.; Roep, B. O.; Romero, P.; Hoos, A.; Davis, M. M.CANCER IMMUNOLOGY IMMUNOTHERAPY201160115
25Dendritic Cell Subsets as Vectors and Targets for Improved Cancer TherapyPalucka, Karolina; Ueno, Hideki; Roberts, Lee; Fay, Joseph; Banchereau, JacquesCANCER IMMUNOLOGY AND IMMUNOTHERAPY2011344173
26Sources of diversity in T cell epitope discoveryChang, Cynthia Xin Lei; Dai, Lingyun; Tan, Zhen Wei; Choo, Joanna Ai Ling; Bertoletti, Antonio; Grotenbreg, Gijsbert M.FRONTIERS IN BIOSCIENCE-LANDMARK2011163014
27A critical assessment for the value of markers to gate-out undesired events in HLA-peptide multimer staining protocolsAttig, Sebastian; Price, Leah; Janetzki, Sylvia; Kalos, Michael; Pride, Michael; McNeil, Lisa; Clay, Tim; Yuan, Jianda; Odunsi, Kunle; Hoos, Axel; Romero, Pedro; Britten, Cedrik M.JOURNAL OF TRANSLATIONAL MEDICINE20119
28Interrogating the repertoire: broadening the scope of peptide-MHC multimer analysisDavis, Mark M.; Altman, John D.; Newell, Evan W.NATURE REVIEWS IMMUNOLOGY2011118551
29Cancer immunotherapy - revisitedLesterhuis, W. Joost; Haanen, John B. A. G.; Punt, Cornelis J. A.NATURE REVIEWS DRUG DISCOVERY2011108591
30Melanoma vaccines: developments over the past 10 yearsKlein, Oliver; Schmidt, Christopher; Knights, Ashley; Davis, Ian D; Chen, Weisan; Cebon, JonathanEXPERT REVIEWS OF VACCINES2011106853
31Therapeutic cancer vaccines: are we there yet?Klebanoff, Christopher A.; Acquavella, Nicolas; Yu, Zhiya; Restifo, Nicholas P.IMMUNOLOGICAL REVIEWS201123927
32Isolation and preservation of peripheral blood mononuclear cells for analysis of islet antigen-reactive T cell responses: position statement of the T-Cell Workshop Committee of the Immunology of Diabetes SocietyMallone, R.; Mannering, S. I.; Brooks-Worrell, B. M.; Durinovic-Bello, I.; Cilio, C. M.; Wong, F. S.; Schloot, N. C.CLINICAL AND EXPERIMENTAL IMMUNOLOGY2011163133
33Biomarkers in T cell therapy clinical trials.Kalos M. JOURNAL OF TRANSLATIONAL MEDICINE20119138
34Upfront immunization with autologous recombinant idiotype Fab fragment without prior cytoreduction in indolent B-cell lymphomaNavarrete, Marcelo A.; Heining-Mikesch, Kristina; Schueler, Frank; Bertinetti-Lapatki, Cristina; Ihorst, Gabriele; Keppler-Hafkemeyer, Andrea; Doelken, Gottfried; Veelken, HendrikBLOOD201111751483
35Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy BiomarkersButterfield, Lisa H.; Palucka, A. Karolina; Britten, Cedrik M. et al.CLINICAL CANCER RESEARCH201117103064
36T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced LeukemiaKalos, Michael; Levine, Bruce L.; Porter, David L.; Katz, Sharyn; Grupp, Stephan A.; Bagg, Adam; June, Carl H.SCIENCE TRANSLATIONAL MEDICINE2011395
37Evaluation of current cancer immunotherapy: hemato-oncology.Hourigan CS, Levitsky HI.CANCER JOURNAL2011175309
38Dendritic cell vaccines in cancer immunotherapy: from biology to translational medicineXu H, Cao XFRONTIERS OF MEDICINE201154323
39A methodological framework to enhance the clinical success of cancer immunotherapyHoos, Axel; Britten, Cedrik M.; Huber, Christoph; O'Donnell-Tormey, JillNATURE BIOTECHNOLOGY20112910867
40Harmonization of immune biomarker assays for clinical studies.van der Burg SH, Kalos M, Gouttefangeas C, Janetzki S, Ottensmeier C, Welters MJ, Romero P, Britten CM, Hoos A.SCIENCE TRANSLATIONAL MEDICINE20113108
41The impact of harmonization on ELISPOT assay performance.Janetzki S, Britten CMMETHODS MOL BIOL.201279225
42Response determination criteria for ELISPOT: toward a standard that can be applied across laboratories.Moodie Z, Price L, Janetzki S, Britten CM.METHODS MOL BIOL.2012792185
43Defining the Critical Hurdles in Cancer ImmunotherapyFox BA, Schendel DJ, Butterfield LH, et al.JOURNAL OF TRANSLATIONAL MEDICINE  20119214
44Objective, user-independent ELISPOT data analysis based on scientifically validated principlesZhang W, Lehmann PVMETHODS MOL BIOL.2012792155
45New concepts for building vocabulary for cell image ontologies.Plant AL, Elliott JT, Bhat TN.BMC BIOINFORMATICS201112487
46Novel cancer immunotherapy agents with survival benefit: recent successes and next stepsSharma P, Wagner K, Wolchok JD, and Allison JPNATURE REVIEWS CANCER201111805
47The immuno-oncology framework: Enabling a new era of cancer therapyHoos A, Britten CMONCOIMMUNOLOGY2012131
48Design of therapeutic vaccines: hepatitis B as an exampleKutscher, S; Bauer, T; Dembek, C; Sprinzl, M; Protzer, UMICROBIAL BIOTECHNOLOGY201252270
49Safety and immunogenicity of long HSV-2 peptides complexed with rhHsc70 in HSV-2 seropositive personsWald, A; Koelle, DM; Fife, K; Warren, T; LeClair, K; Chicz, RM; Monks, S; Levey, DL; Musselli, C; Srivastava, PKVACCINE201129478520
50The Stanford Data Miner: a novel approach for integrating and exploring heterogeneous immunological dataSiebert JC, Munsil W, Rosenberg-Hasson Y, Davis MM, Maecker HTJOURNAL OF TRANSLATIONAL MEDICINE  20121062
51Harmonization of the intracellular cytokine staining assayWelters, MJP; Gouttefangeas, C; Ramwadhdoebe, TH; Letsch, A; Ottensmeier, CH; Britten, CM; van der Burg, SHCANCER IMMUNOLOGY IMMUNOTHERAPY2012617967
52The simultaneous ex vivo detection of low-frequency antigen-specific CD4+ and CD8+ T-cell responses using overlapping peptide pools.Singh SK, Meyering M, Ramwadhdoebe TH, Stynenbosch LF, Redeker A, Kuppen PJ, Melief CJ,Welters MJ, van der Burg SHCANCER IMMUNOLOGY IMMUNOTHERAPY2012
53DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8(+) T-cell responses and increases PSA doubling time.Chudley L, McCann K, Mander A, Tjelle T, Campos-Perez J, Godeseth R, Creak A, Dobbyn J, Johnson B, Bass P, Heath C, Kerr P, Mathiesen I, Dearnaley D, Stevenson F, Ottensmeier CCANCER IMMUNOLOGY IMMUNOTHERAPY2012
54Immune Monitoring Design within the Developmental Pipeline for an Immunotherapeutic or Preventive VaccineJanetzki S, Romero P, Roederer M, Bolton DL, Jandus C. VACCINOLOGY: PRINCIPLES AND PRACTICE. Edited by W. John W. Morrow, Nadeem A. Sheikh, Clint S. Schmidt, D. Huw Davies2012Chapter 28419
55Distinguishing Latent from Active Mycobacterium tuberculosis Infection Using Elispot  Assays: Looking Beyond Interferon-gammaCamilla Tincati 1, Amedeo J. Cappione III 2 and Jennifer E. Snyder-Cappione CELLS20121289
56Adjunct immunotherapies for tuberculosisUhlin M, Andersson J, Zumla A, Maeurer MJOURNAL OF INFECTIOUS DISEASES2012205325
57T Cell Assays and MIATA: The Essential Minimum for Maximum Impact.Britten CM, Janetzki S, Butterfield LH, Ferrari G, Gouttefangeas C, Huber C, Kalos M, Levitsky HI, Maecker HT, Melief CJ, O'Donnell-Tormey J, Odunsi K, Old LJ, Ottenhoff TH, Ottensmeier C, Pawelec G, Roederer M, Roep BO, Romero P, van der Burg SH, Walter S, Hoos A, Davis MM.IMMUNITY201227371
58Advancing the field of cancer immunotherapy: MIATA consensus guidelines become available to improve data reporting and interpretation for T-cell immune monitoring.Hoos A, Janetzki S, Britten CM.ONCOIMMUNOLOGY2012191457
59Trial watch: Peptide vaccines in cancer therapy.Vacchelli E, Martins I, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.ONCOIMMUNOLOGY2012191557
60A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions van Steenwijk, Peggy J. de Vos; Ramwadhdoebe, Tamara H.; Lowik, Margriet J. G.; et al.CANCER IMMUNOLOGY IMMUNOTHERAPY 20126191485
61Flow Cytometry Jahan-Tigh, Richard R.; Ryan, Caitriona; Obermoser, Gerlinde; et al.JOURNAL OF INVESTIGATIVE DERMATOLOGY2012132101
62Humoral anti-KLH responses in cancer patients treated with dendritic cell-based immunotherapy are dictated by different vaccination parameters Aarntzen, Erik H. J. G.; de Vries, I. Jolanda M.; Goertz, Joop H.; et al.CANCER IMMUNOLOGY IMMUNOTHERAPY201261112003
63Addition of interferon-alpha to the p53-SLP (R) vaccine results in increased production of interferon-gamma in vaccinated colorectal cancer patients: A phase I/II clinical trial Zeestraten, Eliane C. M.; Speetjens, Frank M.; Welters, Marij J. P.; et al.INTERNATIONAL JOURNAL OF CANCER201313271581
64Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor typesAscierto PA, Kalos M, Schaer DA, Callahan MK, Wolchok JDCLINICAL CANCER RESEARCH20131951005
65The development of standard samples with a defined number of antigen-specific T cells to harmonize T cell assays: a proof-of-principle study.Singh SK, Tummers B, Schumacher TN, Gomez R, Franken KL, Verdegaal EM, Laske K, Gouttefangeas C, Ottensmeier C, Welters MJ, Britten CM, van der Burg SHCANCER IMMUNOLOGY IMMUNOTHERAPY2013623489
66Serum-free freezing media support high cell quality and excellent ELISPOT assay performance across a wide variety of different assay protocols.Filbert H, Attig S, Bidmon N, Renard BY, Janetzki S, Sahin U, Welters MJ, Ottensmeier C, van der Burg SH, Gouttefangeas C, Britten CM.CANCER IMMUNOLOGY IMMUNOTHERAPY2013624615
67HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial.van Poelgeest MI, Welters MJ, van Esch EM, Stynenbosch LF, Kerpershoek G, van Persijn van Meerten EL, van den Hende M, Löwik MJ, Berends-van der Meer DM, Fathers LM, Valentijn AR, Oostendorp J, Fleuren GJ, Melief CJ, Kenter GG, van der Burg SH.JOURNAL OF TRANSLATIONAL MEDICINE  20131188
68A Harmonized Approach to Intracellular Cytokine Staining Gating: Results from an International Multi-Consortia Proficiency Panel Conducted by the Cancer Immunotherapy Consortium (CIC/CRI)McNeil LK, Price L, Britten CM, Jaimes M, Maecker H, Odunsi K, Matsuzaki J, Janet S. Staats, Jerill Thorpe, Jianda Yuan and Sylvia JanetzkiCYTOMETRY PART A2013
69HLA-A2-restricted Cytotoxic T Lymphocyte Epitopes from Human Hepsin as Novel Targets for Prostate Cancer ImmunotherapyGuo J, Li G, Tang J, Cao XB, Zhou QY, Fan ZJ, Zhu B, Pan XHSCANDINAVIAN JOURNAL IMMUNOLOGY201331
70Quality control, analysis and secure sharing of Luminex® immunoassay data using the open source LabKey Server platform.Eckels J, Nathe C, Nelson EK, Shoemaker SG, Nostrand EV, Yates NL, Ashley VC, Harris LJ, Bollenbeck M, Fong Y, Tomaras GD, Piehler B.BMC BIOINFORMATICS2013145
71Immune responses to cancer: are they potential biomarkers of prognosis?Whiteside TL .FRONTIERS ONCOLOGY2013107
72Biomarkers in T-cell therapy clinical trials  Lacey, S.F., Kalos, M.CYTOTHERAPY 2013156632
73Pushing the frontiers of T-cell vaccines: Accurate measurement of human T-cell responses  Saade, F., Gorski, S.A., Petrovsky, N.EXPERT REVIEW OF VACCINES201211121459
74Neue perspektiven in der immunologischen krebstherapie | [Cancer immunotherapy - Novel perspectives]  Rothschild, S.I., Zippelius, A.THERAPEUTISCHE UMSCHAU20126910559
75Evolution of end points for cancer immunotherapy trials  Hoos, AANNALS OF ONCOLOGY201223viii47
76Cardiovascular toxicity and titin cross-reactivity of affinity enhanced T cells in myeloma and melanomaLinette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, Litzky L, Bagg A, Carreno BM, Cimino PJ, Binder-Scholl GK, Smethurst DP, Gerry AB, Pumphrey NJ, Bennett AD, Brewer JE, Dukes J, Harper J, Tayton-Martin HK, Jakobsen BK, Hassan NJ, Kalos M, June CHBLOOD2013Epub
77CD39 is involved in mediating suppression by Mycobacterium bovis BCG-activated human CD8+ CD39+regulatory T cells.Boer MC, van Meijgaarden KE, Bastid J, Ottenhoff TH, Joosten SAEUROPEAN JOURNAL IMMUNOLOGY2013Epub
78Conference Scene: Immune signatures in the tumor and beyondKandalaft LE, Kalos M, Melief CLM, Speiser DE & Coukos G. FUTURE MEDICINE201248761
79Approaches to Immunologic Monitoring of Clinical TrialsButterfield LH, Vujanovic L, Pardee ATHE TUMOR IMMUNOENVIRONMENT2013663
80Systems biological approaches to measure and understand vaccine immunity in humansShuzhao Li, Helder I. Nakaya, Dmitri A. Kazmin, Jason Z. Oh, Bali PulendranSEMINARS IN IMMUNOLOGY2013Epub
81Alternative variants of the human hydin are novel cancer-associated antigens recognized by adaptive immunityKaroline Laske, Yury V. Shebzukhov, Ludger Grosse-Hovest, Dmitri V. Kuprash, Svetlana V. Khlgatian, Ekaterina P. Koroleva, Alexey Y. Sazykin, Dmitry N. Penkov, Pavel V. Belousov, Stefan Stevanovic, Verona Vass, Steffen Walter, David Eisel, Barbara Schmid-Horch, Sergei A. Nedospasov, Hans-Georg Rammensee, and Cecile GouttefangeasCANCER IMMUNOLOGY RESEARCH2013Epub
82Structured reporting of T cell assay resultsJanetzki, S., Hoos, A., Melief, C.J.M., Odunsi, K., Romero, R., and Britten, C.M.CANCER IMMUNITY201313213
83T cell immune monitoring assays to guide the development of new cancer vaccinesBritten CM, Janetzki S, Gouttefangeas C, Welters MJP, Kalos M, Ottensmeier C, Hoos A, Van der Burgh SCANCER VACCINES: FROM RESEARCH TO CLINICAL PRACTICE20112nd EditionChapter 12156
84Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanomaLinette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, Litzky L, Bagg A, Carreno BM, Cimino PJ, Binder-Scholl GK, Smethurst DP, Gerry AB, Pumphrey NJ, Bennett AD, Brewer JE, Dukes J, Harper J, Tayton-Martin HK, Jakobsen BK, Hassan NJ, Kalos M, June CHBLOOD2013Epub
85Stromal and hematopoietic cells in secondary lymphoid organs: partners in immunity.Malhotra D, Fletcher AL, Turley SJ.IMMUNOL REV20132511160
86Recent progress in canine tumor vaccination: potential applications for human tumor vaccines.Sofie Denies, Niek N SandersEXPERT REV VACCINES201211111375
87Dendritic cell engineering for tumor immunotherapy: from biology to clinical translation.Arpit Bhargava, Dinesh Mishra, Smita Banerjee, Pradyumna Kumar MishraIMMUNOTHERAPY201247703
88Immunological monitoring to rationally guide AAV gene therapy.Britten CM, Walter S and Janetzki SFRONTIERS IN IMMUNOLOGY201342731
89A Helicopter Perspective on TB Biomarkers: Pathway and Process Based Analysis of Gene Expression Data Provides New Insight into TB PathogenesisJoosten SA, Fletcher HA, Ottenhoff THMPLoS ONE201389
90Overnight Resting of PBMC Changes Functional Signatures of Antigen Specific T- Cell Responses: Impact for Immune Monitoring within Clinical TrialsSarah Kutscher, Claudia J. Dembek, Simone Deckert, Carolina Russo, Nina Koerber, Johannes R. Bogner, Fabian Geisler, Andreas Umgelter, Michael Neuenhahn, Julia Albrecht, Antonio Cosma, Ulrike Protzer, Tanja Bauer
PLOS ONE2013810e76215
91Repositioning therapeutic cancer vaccines in the dawning era of potent immune interventionsAdrian Bot, Francesco Marincola, and Kent A SmithEXPERT REVIEW OF VACCINES201312101219
92Report from the second cytomegalovirus and immunosenescence workshop.Mark Wills, Arne Akbar, Mark Beswick, et al.IMMUNITY & AGEING20118110
93Mobilizing and evaluating anticancer T cells: pitfalls and solutionsCéline Robert-Tissot, Linh T Nguyen, Pamela S Ohashi, and Daniel E SpeiserEXPERT REVIEW OF VACCINES2013Epubdoi: 10.1586/14760584.2013.843456
94Assessment of Immune Responses in Biotherapy Trials and Clinical EndpointsWhiteside, TLADVANCES IN TUMOR IMMUNOLOGY AND IMMUNOTHERAPY; CURRENT CANCER RESEARCH2014Rosenblatt, J.D.; Podack, E.R.; Barber, G.N.; Ochoa, A. (Eds.)Springer New York343
95The long-term immune response after HPV16 peptide vaccination in women with low-grade pre-malignant disorders of the uterine cervix: a placebo-controlled phase II study.de Vos van Steenwijk PJ, van Poelgeest MI, Ramwadhdoebe TH, et al.CANCER IMMUNOLOGY IMMUNOTHERAPY
96Multimer monitoring of CMV-specific T cells in research and in clinical applicationsSylvia Borchers, Justyna Ogonek, Pavankumar Reddy Varanasi, Sabine Tischer, Melanie Bremm, Britta Eiz-Vesper, Ulrike Koehl, Eva Maria Weissinger DIAGNOSTIC MICROBIOLOGY & INFECTIOUS DISEASE2013Epubdoi:10.1016/j.diagmicrobio.2013.11.007
97Biomarkers for immune intervention trials in type 1 diabetesMallone, R., Roep, B.OCLINICAL IMMUNOLOGY20131493286
98Identification of CDCA1-derived long peptides bearing both CD4+ and CD8+ T-cell epitopes: CDCA1-specific CD4+ T-cell immunity in cancer patients Tomita, Y., Yuno, A., Tsukamoto, H., Senju, S., Yoshimura, S., Osawa, R., Kuroda, Y., (...), Nishimura, Y.INTERNATIONAL JOURNAL OF CANCER20141342352
99Maximizing output from current glioma vaccine trials to construct robust next-generation immunotherapiesMigliorini, D., Dietrich, P.-Y., Walker, P.R.IMMUNOTHERAPY20135111147
100Identification of promiscuous KIF20A long peptides bearing both CD4 + and CD8+ T-cell epitopes: KIF20A-specific CD4 + T-cell immunity in patients with malignant tumor Tomita, Y., Yuno, A., Tsukamoto, H., Senju, S., Kuroda, Y., Hirayama, M., Irie, A., (...), Nishimura, Y.CLINICAL CANCER RESEARCH201319164508
101Cancer vaccines: Identification of biomarkers predictive of clinical efficacy Harrop, R.HUMAN VACCINES AND IMMUNOTHERAPEUTICS201394800
102Vaccine against autoimmune disease: Antigen-specific immunotherapy Anderson, R.P., Jabri, BCURRENT OPINION IN IMMUNOLOGY2013253410
103Tumor-Infiltrating Lymphocytes and Their Role in Solid Tumor ProgressionWhiteside, T.L.INTERACTIONS OF IMMUNE AND CANCER CELLS2014Srpingerdoi:10.1007/978-3-7091-1300-4_6111
104Cancer, Aging and Immune ReconstitutionZanussi, Stefania; Serraino, Diego; Dolcetti, Riccardo; Berretta, Massimiliano; Paoli, Paolo D.ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY20131391310
105Dendritic cells in cancer immunotherapy clinical trials: are we making progress?Lisa H. ButterfieldFRONT. IMMUNOL.2013Epubdoi: 10.3389/fimmu.2013.00454
106Computational resources for high-dimensional immune analysis from the Human Immunology Project ConsortiumVladimir Brusic, Raphael Gottardo, Steven H Kleinstein, Mark M Davis, Mark M Davis, David A Hafler, Helen Quill, A Karolina Palucka, Gregory A Poland, Bali Pulendran, Ellis L Reinherz,
Kenneth D Stuart & Alkis Togias for HIPC steering committee
NATURE BIOTECHNOLOGY2014Epubdoi:10.1038/nbt.2777
107Implementing combinatorial immunotherapeutic regimens against cancer: The concept of immunological conditioningDominik Wolf, Annkristin Heine, Peter BrossartONCOIMMUNOLOGY2013Epub3:e27588
108Specific active immunotherapy with a VEGF vaccine in patients with advanced solid tumors. Results of the CENTAURO antigen dose escalation phase I clinical trialJ.V. Gavilondoa, F. Hernández-Bernala, M. Ayala Ávilaa, A.V. de la Torreb, J. de la Torrec, Y. Morera-Díaza, M. Bequet-Romeroa, J. Sáncheza, C.M. Valenzuelaa, Y. Martínb, K.-H. Selman-Houseinc, A. Garabitob, O.C. Lazoa, for the CENTAURO Group of InvestigatorsVACCINE2014Epubhttp://dx.doi.org/10.1016/j.vaccine.2013.11.102
109Challenges in the development of a survivin vaccine (SurVaxM) for malignant gliomaRobert A Fenstermaker and Michael J CiesielskiEXPERT REVIEW OF VACCINES2014133377
110Immune Monitoring in Cancer Vaccine Clinical Trials: Critical Issues of Functional Flow Cytometry-Based Assays.Iole Macchia, Francesca Urbani, Enrico ProiettiBIOMED RESEARCH INTERNATIONAL2013EPubDOI:10.1155/2013/726239
111An Enzyme-Linked Immunospot Assay for the Detection of Human Respiratory Syncytial Virus F-Specific IFNγ-producing T CellsPatton K, Aslam S, Lin J, Yu L, Lambert S, Dawes G, Esser MT, Woo J, Janetzki S, Cherukuri A.CLINICAL AND VACCINE IMMUNOLOGY2014EPubhttp://cvi.asm.org/content/early/2014/02/20/CVI.00736-13.long
112Human papillomavirus 16 E2-, E6- and E7-specific T-cell responses in children and their mothers who developed incident cervical intraepithelial neoplasia during a 14-year follow-up of the Finnish Family HPV cohort.Koskimaa HM, Paaso AE, Welters MJ, Grénman SE, Syrjänen KJ, van der Burg SH, Syrjänen SMJOURNAL TRNALATIONAL MEDICINE20141244
113T-cell regulation in lepromatous leprosy.Kidist Bobosha, Louis Wilson, Krista E van Meijgaarden, Yonas Bekele, Martha Zewdie, Jolien J van der Ploeg-van Schip, Markos Abebe, Jemal Hussein, Saraswoti Khadge, Kapil D Neupane, Deanna A Hagge, Ekaterina S Jordanova, Abraham Aseffa, Tom H M Ottenhoff, Annemieke GelukPLoS NEGLECTED TROPICAL DISEASES 20148e2773
114CD8+ Regulatory T Cells, and Not CD4+ T Cells, Dominate Suppressive Phenotype and Function after In Vitro Live Mycobacterium bovis-BCG Activation of Human Cells.Boer MC, van Meijgaarden KE, Joosten SA, Ottenhoff THPLOS ONE20149e94192
115Thymic Stromal Lymphopoietin-Mediated Extramedullary Hematopoiesis Promotes Allergic Inflammation.Mark C Siracusa, Steven A Saenz, Elia D Tait Wojno, Brian S Kim, Lisa C Osborne, Carly G Ziegler, Alain J Benitez, Kathryn R Ruymann, Donna L Farber, Patrick M Sleiman, Hakon Hakonarson, Antonella Cianferoni, Mei-Lun Wang, Jonathan M Spergel, Michael R Comeau, David ArtisIMMUNITY2013391158
116Immunostimulatory activity of lifespan-extending agents.José Manuel Bravo-San Pedro, Laura SenovillaAGING20135793
117Establishment and maintenance of a PBMC repository for functional cellular studies in support of clinical vaccine trials.Sambor A, Garcia A, Berrong M, Pickeral J, Brown S, Rountree W, Sanchez A, Pollara J, Frahm N, Keinonen S, Kijak GH, Roederer M, Levine G, D'Souza MP, Jaimes M, Koup R, Denny T, Cox J, Ferrari G.JOURNAL OF IMMUNOLOGICAL METHODS2014Epubdoi: 10.1016/j.jim.2014.04.005
118The role of the reporting framework MIATA within current efforts to advance immune monitoringJanetzki S, Britten CMJOURNAL OF IMMUNOLOGICAL METHODS
2014Epubdoi: 10.1016/j.jim.2014.05.003
119Harmonisation of short-term in vitro culture for the expansion of antigen-specific CD8+ T cells with detection by ELISPOT and HLA-multimer staining.Lindsey Chudley, Katy J. McCann, Adam Coleman, Angelica M. Cazaly, Nicole Bidmon, Cedrik M. Britten, Sjoerd H. van der Burg, Cecile Gouttefangeas, Camilla Jandus, Karoline Laske, Dominik Maurer, Pedro Romero, Helene Schröder, Linda F. M. Stynenbosch, Steffen Walter, Marij J. P. Welters, Christian H. OttensmeierCANCER IMMUNOL IMMUNOTHER2014Epubhttp://link.springer.com/article/10.1007/s00262-014-1593-0
120Evaluation of tumor response to cytokine-induced killer cells therapy in malignant solid tumors.Li XD, Ji M, Zheng X, Ning ZH, Wu J, Lu B, Wu CP, Jiang JTJOURNAL TRANSLATIONAL MEDICINE20141212215
121Cell-Mediated Immunity to AAV Vectors, Evolving Concepts and Potential SolutionsBasner-Tschakarjan E, Mingozzi F.FRONTIERS IN IMMUNOLOGY2014EPUBdoi: 10.3389/fimmu.2014.00350
122TRANSVAC workshop on standardisation and harmonisation of analytical platforms for HIV, TB and malaria vaccines: 'How can big data help?'.Dutruel C, Thole J, Geels M, Mollenkopf HJ, Ottenhoff T, Guzman CA, Fletcher HA, Leroy O, Kaufmann SH.VACCINE2014EPUBDOI: 10.1016/j.vaccine.2014.06.014
123Challenges in the development of a survivin vaccine (SurVaxM) for malignant glioma.Fenstermaker RA, Ciesielski MJEXPERT REVIEWS OF VACCINES2014Epubdoi:10.1586/14760584.2014.881255
124Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors.Lennerz V, Gross S, Gallerani E, Sessa C, Mach N, Boehm S, Hess D, von Boehmer L, Knuth A, Ochsenbein AF, Gnad-Vogt U, Zieschang J, Forssmann U, Woelfel T, Kaempgen E.CANCER IMMUNOL IMMUNOTHER2014Epubdoi: 10.1007/s00262-013-1516-5
125Comparability and reproducibility of biomedical data.Huang Y, Gottardo RBRIEF BIOINFORM2013EPubdoi: 10.1093/bib/bbs078
126Introduction to a Special Issue of the Journal of Immunological Methods: Building Global Resource Programs to Support HIV/AIDS Clinical Trial StudiesAna M. Sanchez, Thomas N. Denny, and Maurice O’GormanJOURNAL OF IMMUNOLOGICAL METHODS
2014EPubdoi: 10.1016/j.jim.2014.05.016
127Effect of cryopreservation of peripheral blood mononuclear cells (PBMCs) on the variability of an antigen-specific memory B cell ELISpot: Variability of the memory B cell ELISpot assay.Trück J, Mitchell R, Thompson AJ, Morales-Aza B, Clutterbuck EA, Kelly DF, Finn A, Pollard AJ.HUM VACCIN IMMUNOTHER20141081
128Bridging Basic Science and Clinical Research – The EASL Monothematic Conference on Translational Research in Viral HepatitisBoettler T, Moradpour D, Thimme R1, Zoulim F. J HEPATOLOGY2014EPub doi: 10.1016/j.jhep.2014.05.016
129Cryopreservation of MHC multimers: Recommendations for quality assurance in detection of antigen specific T cellsHadrup SR, Maurer D, Laske K, Frøsig TM, Andersen SR, Britten CM, van der Burg SH, Walter S, Gouttefangeas C.CYTOMETRY PART A2014EPubDOI: 10.1002/cyto.a.22575
130Miniaturized and high-throughput assays for analysis of T-cell immunity specific for opportunistic pathogens and HIV.Li Pira G, Ivaldi F, Starc N, Landi F, Locatelli F, Rutella S, Tripodi G, Manca F.CLIN VACCINE IMMUNOL2014EPubdoi: 10.1128/CVI.00660-13
131Stepping up ELISpot: Multi-Level Analysis in FluoroSpot Assays.Janetzki S, Rueger M, Dillenbeck T.CELLS20142731102
132CIMT 2014: Next Waves in Cancer Immunotherapy - Report on the 12th Annual Meeting of the Association for Immunotherapy of CancerMustafa Dikena, Sebastian Boegelb, Christian Grunwitzab, Lena Kranzab, Kerstin Reuterc, Niels van de Roemerab, Fulvia Vascotto, Mathias Vormehra & Sebastian KreiterHUMAN VACCINES & IMMUNOTHERAPEUTICS2014EPubDOI:10.4161/hv.29767
133A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in humanvan Dissel JT, Joosten SA, Hoff ST, Soonawala D, Prins C, Hokey DA, O'Dee DM, Graves A, Thierry-Carstensen B, Andreasen LV, Ruhwald M, de Visser AW, Agger EM, Ottenhoff TH, Kromann I, Andersen PVACCINE2014EPubdoi: 10.1016/j.vaccine.2014.10.036
134Getting personal: Perspectives on individualized treatment duration in M/XDR-TB.Heyckendorf , Olaru ID, Ruhwald M, Lange C.Am J Respir Crit Care Med2014EPubdoi: 10.1164/rccm.201402-0363PP
135Sequential immune monitoring in patients with melanoma and renal cell carcinoma treated with high-dose interleukin-2: immune patterns and correlation with outcomeDavid M. Foureau, Asim Amin, Richard L. White, William Anderson, Chase P. Jones, Terry Sarantou, Iain H. McKillop, Jonathan C. SaloCANCER IMMUNOL IMMUNOTHER2014EPubhttp://link.springer.com/article/10.1007%2Fs00262-014-1605-0
136Flow Cytometry in Cancer Immunotherapy: Applications, Quality Assurance, and FutureCécile Gouttefangeas, Steffen Walter, Marij J. P. Welters, Christian Ottensmeier, Sjoerd H. van der Burg, Cedrik M. Britten, Cliburn Chan in: Cancer Immunology2015http://link.springer.com/chapter/10.1007/978-3-662-44006-3_25471-490
137Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid MalignanciesGregory L. Beatty, Andrew R. Haas, Marcela V. Maus, Drew A. Torigian, Michael C. Soulen, Gabriela Plesa, Anne Chew, Yangbing Zhao, Bruce L. Levine, Steven M. Albelda, Michael Kalos, and Carl H. JuneCANCER IMMUNOL RES2014EPubdoi: 10.1158/2326-6066.CIR-13-0170
138Improvement of IFNg ELISPOT Performance Following Overnight Resting of Frozen PBMC Samples Confirmed Through Rigorous Statistical AnalysisRadleigh Santos, Alcinette Buying, Nazila Sabri, John Yu, Anthony Gringeri, James Bender, Sylvia Janetzki , Clemencia Pinilla and Valeria A. JudkowskiCELLS2015EPubdoi:10.3390/cells4010001
139Abacavir-Reactive Memory T Cells Are Present in Drug Naïve IndividualsAndrew Lucas, Michaela Lucas, Anette Strhyn, Niamh M. Keane, Elizabeth McKinnon, Rebecca Pavlos, Ellen M. Moran, Viola Meyer-Pannwitt, Silvana Gaudieri, Lloyd D’Orsogna, Spyros Kalams, David A. Ostrov, Søren Buus, Bjoern Peters, Simon Mallal, Elizabeth PhillipsPLOS ONE2015EPubhttp://journals.plos.org/plosone/article?id=10.1371/journal.pone.0117160
140Human CD8+ T-cells Recognizing Peptides from Mycobacterium tuberculosis (Mtb) Presented by HLA-E Have an Unorthodox Th2-like, Multifunctional, Mtb Inhibitory Phenotype and Represent a Novel Human T-cell SubsetKrista E. van Meijgaarden, Mariëlle C. Haks, Nadia Caccamo, Francesco Dieli, Tom H. M. Ottenhoff , Simone A. JoostenPLOS PATHOGEN2015EPubDOI: 10.1371/journal.ppat.1004671
141Human fibrocytic myeloid-derived suppressor cells express IDO and promote tolerance via Treg-cell expansion.Zoso A, Mazza EM, Bicciato S, Mandruzzato S, Bronte V, Serafini P, Inverardi L.EUR J IMMUNOL2014EPubdoi: 10.1002/eji.201444522.
142Data analysis as a source of variability of the HLA-peptide multimer assay: from manual gating to automated recognition of cell clustersCécile Gouttefangeas, Cliburn Chan, Sebastian Attig, Tania T. Køllgaard, Hans-Georg Rammensee, Stefan Stevanović, Dorothee Wernet, Per thor Straten, Marij J. P. Welters, Christian Ottensmeier, Sjoerd H. van der Burg, Cedrik M. BrittenCANCER IMMUNOL IMMUNOTHER2015645585
143Cancer Immunotherapy Confers a Global BenefitZahra Aryan, Håkan Mellstedt, Nima Rezaei CANCER IMMUNOL2015111
144Cancer immunotherapy drives implementation science in oncologyDaniel E Speiser, Lukas FlatzHUMAN VACC IMMUNOTHER2014EPubDOI:10.4161/21645515.2014.983000
145Minimum information standards.James A HutchinsonTRANSPLANTATION2015EPubDOI:10.1097/TP.0000000000000693
146Engineering monocyte-derived dendritic cells to secrete interferon-α enhances their ability to promote adaptive and innate anti-tumor immune effector functionsYannick Willemen, Johan M. J. Van den Bergh, Eva Lion, Sébastien Anguille, Vicky A. E. Roelandts, Heleen H. Van Acker, Steven D. I. Heynderickx, Barbara M. H. Stein, Marc Peeters, Carl G. Figdor, Viggo F. I. Van Tendeloo, I. Jolanda de Vries, Gosse J. Adema, Zwi N. Berneman, Evelien L. J. SmitsCANCER IMMUNOL IMMUNOTHER2015EPubdoi: 10.1007/s00262-015-1688-2
147Generation of TCR-Engineered T Cells and Their Use To Control the Performance of T Cell Assays.Bidmon N, Attig S, Rae R, Schröder H, Omokoko TA, Simon P, Kuhn AN, Kreiter S, Sahin U, Gouttefangeas C, van der Burg SH, Britten CM.J IMMUNOL2015EPubdoi: 10.4049/jimmunol.1400958
148Idiotypic DNA vaccination for the treatment of multiple myeloma: safety and immunogenicity in a phase I clinical study.McCann KJ, Godeseth R, Chudley L, Mander A, Di Genova G, Lloyd-Evans P, Kerr JP, Malykh VB, Jenner MW, Orchard KH, Stevenson FK, Ottensmeier CH.CANCER IMMUNOL IMMUNOTHER
149Quantitative TCR:pMHC Dissociation Rate Assessment by NTAmers Reveals Antimelanoma T Cell Repertoires Enriched for High Functional CompetencePhilippe O. Gannon, Sébastien Wieckowski, Petra Baumgaertner, Michaël Hebeisen, Mathilde Allard, Daniel E. Speiser and Nathalie RuferJ IMMUNOL2015EPubdoi: 10.4049/​jimmunol.1403145
150Immune cell profiling to guide therapeutic decisions in rheumatic diseasesJoerg Ermann, Deepak A. Rao, Nikola C. Teslovich, Michael B. Brenner & Soumya RaychaudhuriNAT REV RHEUM2015EPubdoi:10.1038/nrrheum.2015.71
151Adoptive T-cell therapy: a need for standard immune monitoringYarne Klaver, Andre Kunert, Stefan Sleijfer, Reno Debets & Cor HJ LamersIMMUNOTHERAPY2015EPubdoi:10.2217/imt.15.23
152Neonatal regulatory T cells have reduced capacity to suppress dendritic cell functionCesar M. Rueda, Maria Moreno-Fernandez, Courtney M. Jackson, Suhas G. Kallapur, Alan H. Jobe andClaire A. ChougnetEUR J IMMUNOL2015EPubDOI: 10.1002/eji.201445371
153Guidelines for the automated evaluation of Elispot assays.Janetzki S, Price L, Schroeder H, Britten CM, Welters MJ, Hoos A.NAT PROTOC2015EPubDOI: 10.1038/nprot.2015.068
154Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry.Santegoets SJ, Dijkgraaf EM, Battaglia A, Beckhove P, Britten CM, Gallimore A, Godkin A, Gouttefangeas C, de Gruijl TD, Koenen HJ, Scheffold A, Shevach EM, Staats J, Taskén K, Whiteside TL, Kroep JR, Welters MJ, van der Burg SH.CANCER IMMUNOL IMMUNOTHER2015EPubDOI: 10.1007/s00262-015-1729-x
155NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma.RapoportAP,StadtmauerEA, Binder-Scholl GK, Goloubeva O, Vogl DT, Lacey SF, Badros AZ, Garfall A, Weiss B, Finklestein J, Kulikovskaya I, Sinha SK, Kronsberg S, Gupta M, Bond S, Melchiori L, Brewer JE, Bennett AD, Gerry AB, Pumphrey NJ, Williams D, Tayton-Martin HK, Ribeiro L, Holdich T, Yanovich S, Hardy N, Yared J, Kerr N, Philip S, Westphal S, Siegel DL, Levine BL, Jakobsen BK, Kalos M, June CH.NAT MED2015EPubdoi: 10.1038/nm.3910
156Detection and Tracking of NY-ESO-1-Specific CD8+ T Cells by High-Throughput T Cell Receptor β (TCRB) Gene Rearrangements Sequencing in a Peptide-Vaccinated Patient.Miyai M, Eikawa S, Hosoi A, Iino T, Matsushita H, Isobe M, Uenaka A, Udono H, Nakajima J, Nakayama E, Kakimi K.PLOS ONE2015EPub doi: 10.1371/journal.pone.0136086
157Critical issues in cancer vaccine trial designGuy T. Clifton, Holbrook E. Kohrt, George E. PeoplesVACCINE2015EPubdoi:10.1016/j.vaccine.2015.09.019
158Immunotherapies and immune biomarkers in Type 1 diabetes: A partnership for successRekers NV, von Herrath MG, Wesley JDCLIN IMMUNOL2015EPubdoi: 10.1016/j.clim.2015.05.021
159Analysis of cell-mediated immune responses in support of dengue vaccine development effortsAlan L. Rothman, Jeffrey R. Currier, Heather L. Friberg, Anuja MathewVACCINE2015EPubdoi:10.1016/j.vaccine.2015.09.104
160Intracellular Cytokine Staining and Flow Cytometry: Considerations for Application in Clinical Trials of Novel Tuberculosis VaccinesSmith SG, Smits K, Joosten SA, van Meijgaarden KE, Satti I, Fletcher HA, Caccamo N, Dieli F, Mascart F, McShane H, Dockrell HM, Ottenhoff TH; TBVI TB Biomarker Working Group.PLOS ONE2015EPubdoi: 10.1371/journal.pone.0138042
161Enzyme-Linked ImmunoSpot (ELISpot) for Single-Cell Analysis.Janetzki S, Rabin R.METHODS MOL BIOL2015EPubdoi: 10.1007/978-1-4939-2987-0_3
162Short peptide vaccine induces CD4+ T helper cells in patients with different solid cancers.Stefanie Gross, Volker Lennerz, Elisa Gallerani, Nicolas Nicolas Mach, Steffen Böhm, Dagmar Hess, Lotta von Boehmer, Alexander Knuth, Adrian Ochsenbein, Ulrike S Gnad-Vogt, Ulf Forssmann, Thomas Woelfel, and Eckhart KaempgenCANCER IMMUNOL RES2015EPubdoi: 10.1158/2326-6066.CIR-15-0105
163Immunomonitoring in glioma immunotherapy: current status and future perspectivesJonathan B. Lamano, Leonel Ampie, Winward Choy, Kartik Kesavabhotla, Joseph D. DiDomenico, Daniel E. Oyon, Andrew T. Parsa, Orin BlochJ NEURO-ONCOL2015EPubhttp://link.springer.com/article/10.1007/s11060-015-2018-4
164A phase I/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic cells in patients with hepatocellular carcinomaJeong-Hoon Lee, Yoon Lee, Minjong Lee, Min Kyu Heo, Jae-Sung Song, Ki-Hwan Kim, Hyunah Lee, Nam-Joon Yi, Kwang-Woong Lee, Kyung-Suk Suh, Yong-Soo Bae and Yoon Jun KimBR J CANCER2015EPubdoi:10.1038/bjc.2015.430
165Mutanome Engineered RNA Immunotherapy – Towards patient-centered tumor vaccinationMathias Vormehr, Barbara Schroers, Sebastian Boegel, Martin Loewer, Oezlem Tuereci, and Ugur SahinJ IMMUNOL RES2015EPubhttp://downloads.hindawi.com/journals/jir/aip/595363.pdf
166The search for the target antigens of multiple sclerosis, part 2: CD8+ T cells, B cells, and antibodies in the focus of reverse-translational researchR Hohlfeld, K Dornmair, E Meinl, H WekerleLANCET NEUROL2015EPubdoi: 10.1016/S1474-4422(15)00313-0
167Human papillomavirus 16-specific cell-mediated immunity in children born to mothers with incident cervical intraepithelial neoplasia (CIN) and to those constantly HPV negativeHanna-Mari Koskimaa, Anna Paaso, Marij J. P. Welters, Seija Grenman, Kari Syrjänen, Sjoerd H. van der Burg and Stina SyrjänenJ TRANSL MED2015EPubdoi:10.1186/s12967-015-0733-4
168A framework for T cell assaysCedrik M. Britten, Sjoerd H. van der Burg, Cécile GouttefangeasONCOTARGET2016EPubdoi: 10.18632/oncotarget.6181
169The use and abuse of immune indices in nutritional immunology studiesRamesh K. Selvaraj, Revathi Shanmuga-sundara and Ravikumar RengasamyJ APPL POULT RES
2016EPubdoi: 10.3382/japr/pfv077
170Mismatch in epitope specificities between IFNγ inflamed and uninflamed conditions leads to escape from T lymphocyte killing in melanoma.Woods K, Knights AJ, Anaka M, Schittenhelm RB, Purcell AW, Behren A, Cebon JJ IMMUNOTHER CANCER2016EPubhttp://jitc.biomedcentral.com/articles/10.1186/s40425-016-0111-7
1712015 Guidance on cancer immunotherapy development in early‐phase clinical studiesGuidance Development Review Committee et al. CANCER SCI2016EPubhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC4714668/
172Semi-automated and standardized cytometric procedures for multi-panel and multi-parametric whole blood immunophenotyping.Hasan M, Beitz B, Rouilly V, Libri V, Urrutia A, Duffy D, Cassard L, Di Santo JP, Mottez E, Quintana-Murci L, Albert ML, Rogge L; Milieu Intérieur Consortium.CLIN IMMUNOL2015EPubhttp://www.sciencedirect.com/science/article/pii/S1521661614002861
173Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generationsHoos ANAT REV DRUG DISCOV2016EPubhttp://www.nature.com/nrd/journal/vaop/ncurrent/full/nrd.2015.35.html
174First Proposal of Minimum Information About a
Cellular Assay for Regenerative Medicine
Sakurai K, Kurtz A, Stacey G, Sheldon M, Fujibuchi WSTEM CELLS TRANSL MED2016EPubhttp://stemcellstm.alphamedpress.org/content/early/2016/07/12/sctm.2015-0393.full.pdf
175Tumor antigen–specific T cells for immune monitoring of dendritic cell–treated glioblastoma patientsIsabelle Müller, Dominik Altherr, Matthias Eyrich, Brigitte Flesch, Kim S. Friedmann, Ralf Ketter, Joachim Oertel, Eva C. Schwarz, Antje Technau, Steffi Urbschat, Hermann EichlerCYTOTHERAPY2016EPubdoi: http://dx.doi.org/10.1016/j.jcyt.2016.05.014
176Patients with Tuberculosis Have a Dysfunctional Circulating B-Cell Compartment, Which Normalizes following Successful Treatment.Joosten SA, van Meijgaarden KE, Del Nonno F, Baiocchini A, Petrone L, Vanini V, Smits HH, Palmieri F, Goletti D, Ottenhoff TH.PLOS PATHOG2016EPubhttp://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1005687
177Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted VaccinesSpencer D. Martin, Scott D. Brown, Darin A. Wick, Julie S. Nielsen, David R. Kroeger, Kwame Twumasi-Boateng, Robert A. Holt, Brad H. NelsonPLOS One2016Epubhttp://journals.plos.org/plosone/article?id=10.1371/journal.pone.0155189
178Targeting the Heterogeneity of Cancer with Individualized Neoepitope Vaccines.Türeci Ö, Vormehr M, Diken M, Kreiter S, Huber C, Sahin UCLIN CANCER RES2016EPubDOI: 10.1158/1078-0432.CCR-15-1509
179Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunological and Clinical OutcomesKaty J McCann, Ann Mander, Angelica Cazaly, Lindsey Chudley, Jana Stasakova, Stephen M Thirdborough, Andrew King, Paul Lloyd-Evans, Emily Buxton, Ceri Edwards, Sarah Halford, Andrew Bateman, Ann O'Callaghan, Sally Clive, Alan Anthoney, Duncan I. Jodrell, Toni Weinschenk, Petra Simon, Ugur Sahin, Gareth J Thomas, Freda K Stevenson, Christian H OttensmeierCLIN CANCER RES2016EPubDOI: 10.1158/1078-0432.CCR-15-2507
180Validation of an IFNγ/IL2 FluoroSpot assay for clinical trial monitoringNina Körber, Uta Behrends, Alexander Hapfelmeier, Ulrike Protzer and Tanja BauerJ TRANSL MED2016EPubhttps://translational-medicine.biomedcentral.com/articles/10.1186/s12967-016-0932-7
181Managing Multi-center Flow Cytometry Data for Immune Monitoring.White S, Laske K, Welters MJ, Bidmon N, van der Burg SH, Britten CM, Enzor J, Staats J, Weinhold KJ, Gouttefangeas C, Chan CCANCER INFORM2015Epubhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC4463798/pdf/cin-suppl.7-2014-111.pdf
182Mycobacterium bovis BCG Vaccination Induces Divergent Proinflammatory or Regulatory T Cell Responses in AdultsMardi C. Boer, Corine Prins, Krista E. van Meijgaarden, Jaap T. van Dissel, Tom H. M. Ottenhoff, and Simone A. JoostenCLIN VACCINE IMMUNOL2015EPubhttp://cvi.asm.org/content/22/7/778.long
183Multi-peptide immunotherapeutic vaccine for renal cell carcinoma: getting the troops all worked up.Yaddanapudi K, Eaton JWTRANSL ANDROL UROL2012Epubhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC4160063/pdf/tau-01-04-229.pdf
184Validation of immunomonitoring methods for application in clinical studies: The HLA-peptide multimer staining assay.Chandran PA, Laske K, Cazaly A, Rusch E, Schmid-Horch B, Rammensee HG, Ottensmeier CH, Gouttefangeas CCYTOMETRY B2016EPubDOI: 10.1002/cyto.b.21397
185Reduced potency of cytotoxic T lymphocytes from patients with high-risk myelodysplastic syndromesKristoffer Sand, Jakob Theorell, Øystein Bruserud, Yenan T. Bryceson, Astrid Olsnes KittangCANCER IMMUNOL IMMUNOTHER2016EPubdoi:10.1007/s00262-016-1865-y
186Minimum information about tolerogenic antigen-presenting cells (MITAP): a first step towards reproducibility and standardisation of cellular therapiesPhillip Lord, Rachel Spiering, Juan C. Aguillon, Amy E. Anderson, Silke Appel, Daniel Benitez-Ribas, Anja ten Brinke, Femke Broere, Nathalie Cools, Maria Cristina Cuturi, Julie Diboll, Edward K. Geissler, Nick Giannoukakis, Silvia Gregori, S. Marieke van Ham, Staci Lattimer, Lindsay Marshall, Rachel A. Harry, James A. Hutchinson, John D. Isaacs, Irma Joosten, Cees van Kooten, Ascension Lopez Diaz de Cerio, Tatjana Nikolic, Haluk Barbaros Oral, Ljiljana Sofronic-Milosavljevic, Thomas Ritter, Paloma Riquelme, Angus W. Thomson, Massimo Trucco, Marta Vives-Pi, Eva M. Martinez-Caceres, Catharien M.U. HilkensPEERJ2016EPubhttps://peerj.com/articles/2300/
187The importance of correctly timing cancer immunotherapyElham Beyranvand Nejad, Marij J.P. Welters, Ramon Arens & Sjoerd H. van der Burg
EXPERT OPINION ON BIOLOGICAL THERAPY2017EPubhttp://www.tandfonline.com/doi/abs/10.1080/14712598.2017.1256388
188Elispot for Rookies (And Experts too))Janetzki SSpringer Book Series "Techniques in Life Science and Biomedicine for the Non-Expert"2016EPubhttps://link.springer.com/book/10.1007/978-3-319-45295-1
189Immunostimulatory activity of lifespan-extending agentsBravo-San Pedro JM, Senovilla LAGING2013EPubhttp://www.aging-us.com/article/100619/text
190Teaching advanced flow cytometry in Africa: 10 years of lessons learnedNemes E, Burgers WA, Riou C, Andersen-Nissen E, Ferrari G, Gray CM, Scriba T.CYTOMETRY A2016EPubhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5326675/
191The tumor-associated antigen RHAMM (HMMR/CD168) is expressed by monocyte-derived dendritic cells and presented to T cells.Willemen Y, Van den Bergh JM, Bonte SM, Anguille S, Heirman C, Stein BM, Goossens H, Kerre T, Thielemans K, Peeters M, Van Tendeloo VF, Smits EL, Berneman ZNONCOTARGET2016EPubhttp://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path[]=12170&pubmed-linkout=1
192Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation.Masucci GV, Cesano A, Hawtin R, Janetzki S, Zhang J, Kirsch I, Dobbin KK, Alvarez J, Robbins PB, Selvan SR, et al.J IMMUNOTHER CANCER2016EPubhttps://jitc.biomedcentral.com/articles/10.1186/s40425-016-0178-1
193Immuno-oncology combinations: raising the tail of the survival curve.Harris SJ, Brown J, Lopez J, Yap TA.CANCER BIOL MED2016EPubhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944548/
194Twelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patientsGross S, Erdmann M, Haendle I, Voland S, Berger T, Schultz E, Strasser E, Dankerl P, Janka R, Schliep S, et al.JCI INSIGHT2017EPubhttps://insight.jci.org/articles/view/91438
195First Proposal of Minimum Information About a Cellular Assay for Regenerative MedicineSakurai K, Kurtz A, Stacey G, Sheldon M, Fujibuchi W.STEM CELLS TRANSL MED2016EPubhttp://onlinelibrary.wiley.com/doi/10.5966/sctm.2015-0393/abstract
196Targeting Carcinoembryonic Antigen with DNA Vaccination: On-Target Adverse Events Link with Immunologic and Clinical OutcomesMcCann KJ, Mander A, Cazaly A, Chudley L, Stasakova J, Thirdborough SM, King A, Lloyd-Evans P, Buxton E, Edwards C, Halford S, Bateman A, O'Callaghan A, Clive S, Anthoney A, Jodrell DI, Weinschenk T, Simon P, Sahin U, Thomas GJ, Stevenson FK, Ottensmeier CHCLIN CANCER RES2016EPubhttp://clincancerres.aacrjournals.org/content/22/19/4827.long